6 [5] C. A. Flynn, A. L. Helwig, and L. N. Meurer, “Bacterial vagi- nosis in pregnancy and the risk of prematurity: a meta- analysis,” The Journal of Family Practice, vol. 48, no. 11, pp. 885–892, 1999. [6] H. L. Martin Jr., B. A. Richardson, P. M. Nyange, et al., “Vagi- nal lactobacilli, microbial ﬂora, and risk of human immunod- eﬁciency virus type 1 and sexually transmitted disease acqui- sition,” Journal of Infectious Diseases, vol. 180, no. 6, pp. 1863– 1868, 1999. [7] S. Ayehunie, C. Cannon, S. Lamore, et al., “Organotypic hu- man vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products,” Tox- icology in Vitro, vol. 20, no. 5, pp. 689–698, 2006. [8] A. M. Geshnizgani and A. B. Onderdonk, “Deﬁned medium simulating genital tract secretions for growth of vaginal mi- croﬂora,” Journal of Clinical Microbiology, vol. 30, no. 5, pp. 1323–1326, 1992. [9] J. E. Davis, J. H. Frudenfeld, and J. L. Goddard, “Comparative evaluation of Monistat and Mycostatin in the treatment of vul- vovaginal candidiasis,” Obstetrics & Gynecology, vol. 44, no. 3, pp. 403–406, 1974. [10] P. R. Sawyer, R. N. Brogden, R. M. Pinder, T. M. Speight, and G. S. Avery, “Miconazole: a review of its antifungal activity and therapeutic eﬃcacy,” Drugs, vol. 9, no. 6, pp. 406–423, 1975. [11] E. Ozyurt, M. B. Toykuliyeva, I. L. Danilyans, O. Morton, and G. Baktir, “Eﬃcacy of 7-day treatment with metronida- zole+miconazole (Neo-Penotran )-a triple-active pessary for the treatment of single and mixed vaginal infections,” Interna- tional Journal of Gynecology & Obstetrics, vol. 74, no. 1, pp. 35–43, 2001. [12] T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity as- says,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. [13] R. Hertle, S. Brutsche, W. Groeger, et al., “Speciﬁc phos- phatidylethanolamine dependence of Serratia marcescens cy- totoxin activity,” Molecular Microbiology, vol. 26, no. 5, pp. 853–865, 1997. [14] S. Niruthisard, R. E. Roddy, and S. Chutivongse, “The eﬀects of frequent nonoxynol-9 use on the vaginal and cervical mu- cosa,” Sexually Transmitted Diseases, vol. 18, no. 3, pp. 176– 179, 1991. [15] I. F. Hoﬀman, T. E. Taha, N. S. Padian, et al., “Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa,” AIDS, vol. 18, no. 16, pp. 2191–2195, 2004. [16] P. Eckstein, M. C. Jackson, N. Millman, and A. J. Sobrero, “Comparison of vaginal tolerance tests of spermicidal prepa- rations in rabbits and monkeys,” Journal of Reproduction and Fertility, vol. 20, no. 1, pp. 85–93, 1969. [17] L. J. Zaneveld, D. P. Waller, R. A. Anderson, et al., “Eﬃcacy and safety of a new vaginal contraceptive antimicrobial for- mulation containing high molecular weight poly(sodium 4- styrenesulfonate),” Biology of Reproduction, vol. 66, no. 4, pp. 886–894, 2002. [18] O. J. D’Cruz, B. Waurzyniak, and F. M. Uckun, “Mucosal tox- icity studies of a gel formulation of native pokeweed antivi- ral protein,” Toxicologic Pathology, vol. 32, no. 2, pp. 212–221, 2004. [19] M. M. Dhondt, E. Adriaens, J. V. Roey, and J. P. Remon, “The evaluation of the local tolerance of vaginal formulations con- taining dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test,” European Journal of Pharma- ceutics and Biopharmaceutics, vol. 60, no. 3, pp. 419–425, 2005. Infectious Diseases in Obstetrics and Gynecology [20] G. F. Doncel, N. Chandra, and R. N. Fichorova, “Preclinical assessment of the proinﬂammatory potential of microbicide candidates,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 37, supplement, pp. S174–S180, 2004. [21] L. Van Damme, G. Ramjee, M. Alary, et al., “Eﬀectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmis- sion in female sex workers: a randomised controlled trial,” The Lancet, vol. 360, no. 9338, pp. 971–977, 2002. [22] M. Chvapil, W. Droegemueller, J. A. Owen, C. D. Eskelson, and K. Betts, “Studies of nonoxynol-9. I. The eﬀect on the vaginas of rabbits and rats,” Fertility and Sterility, vol. 33, no. 4, pp. 445–450, 1980. [23] K. V. R. Reddy, C. Aranha, S. M. Gupta, and R. D. Yedery, “Evaluation of antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies,” Reproduction, vol. 128, no. 1, pp. 117–126, 2004. [24] F. C. Krebs, S. R. Miller, B. J. Catalone, et al., “Sodium dode- cyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal ker- atinocytes,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 7, pp. 1954–1960, 2000. [25] F. C. Krebs, S. R. Miller, B. J. Catalone, et al., “Comparative in vitro sensitivities of human immune cell lines, vaginal and cer- vical epithelial cell lines, and primary cells to candidate micro- bicides nonoxynol 9, C31G, and sodium dodecyl sulfate,” An- timicrobial Agents and Chemotherapy, vol. 46, no. 7, pp. 2292– 2298, 2002. [26] R. N. Fichorova, M. Bajpai, N. Chandra, et al., “Interleukin (IL)-1, IL-6 and IL-8 predict mucosal toxicity of vaginal mi- crobicidal contraceptives,” Biology of Reproduction, vol. 71, no. 3, pp. 761–769, 2004. [27] J. Cleveland, T. J. Montville, I. F. Nes, and M. L. Chikindas, “Bacteriocins: safe, natural antimicrobials for food preserva- tion,” International Journal of Food Microbiology, vol. 71, no. 1, pp. 1–20, 2001. [28] C. Aranha, S. Gupta, and K. V. R. Reddy, “Contraceptive eﬃ- cacy of antimicrobial peptide Nisin: in vitro and in vivo stud- ies,” Contraception, vol. 69, no. 4, pp. 333–338, 2004. [29] S. Maher and S. McClean, “Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intesti- nal epithelial cells in vitro,” Biochemical Pharmacology, vol. 71, no. 9, pp. 1289–1298, 2006. [30] J. A. McGroarty, L. Tomeczek, D. G. Pond, G. Reid, and A. W. Bruce, “Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal com- pound nonoxynol-9,” Journal of Infectious Diseases, vol. 165, no. 6, pp. 1142–1144, 1992. [31] M. K. Staﬀord, H. Ward, A. Flanagan, et al., “Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse ef- fects,” Journal of Acquired Immune Deﬁciency Syndromes and Human Retrovirology, vol. 17, no. 4, pp. 327–331, 1998. [32] L. M. Pascual, M. B. Daniele, C. Pa´jaro, and L. Barberis, “Lactobacillus species isolated from the vagina: identiﬁcation, hydrogen peroxide production and nonoxynol-9 resistance,” Contraception, vol. 73, no. 1, pp. 78–81, 2006.